We report a comparative study of the B-and T-cell reactive T-cell repertoire, we isolated a panel of MOGspecific CD4 ⍣ T-cell lines from multiple sclerosis patients responses to the extracellular immunoglobulin (Ig)-like domain of human myelin-oligodendrocyte glycoprotein and normal subjects, and these revealed a heterogeneous response with respect to epitope specificity, cytokine (MOG Igd ) in the blood of patients with multiple sclerosis and healthy controls using a bacterial recombinant human response, MHC (major histocompatibility complex) restriction and T-cell receptor Vβ-chain usage. The protein (rhMOG Igd ). The frequency of anti-rhMOG Igdseropositive samples, as determined by Western blotting, majority of the T-cell lines recognized epitopes in the N-terminal region of MOG (amino acids 1-60). One was significantly higher in the multiple sclerosis group (54%) than in normal random controls (excluding epitope (represented by peptide 27-50) was exclusively recognized by T-cell lines from normal controls. Forty per laboratory workers exposed to MOG) (22%; P ⍧ 0.02). In contrast, there was no difference in rhMOG Igd -induced cent of the MOG-specific T-cell lines analysed displayed a Th-2 or Th-0 cytokine profile and could therefore act as proliferation indices of peripheral blood T cells between patients and controls. To characterize the rhMOG Igdhelper T cells in vivo.
Introduction
The pathogenesis of multiple sclerosis involves multiple et al., 1994) , which was initially identified as the dominant target for autoantibody-mediated demyelination in genetic and environmental factors that interact to disrupt immunological self-tolerance to CNS myelin. In susceptible experimental autoimmune encephalomyelitis (EAE) (Lebar et al., 1986) . individuals this results in a chronic inflammatory response in the CNS associated with demyelination, axonal loss and MOG is a CNS myelin-specific, type I membrane protein encoded within the telomeric region of the major ultimately the formation of gliotic scar tissue. Identification of the autoantigens and immune effector mechanism histocompatibility complex (MHC) distal to the MHC F locus (Gardinier et al., 1992; Pham-Dinh et al., 1995) . The mature responsible for this pathology is essential for the future development of diagnostic and therapeutic strategies for protein is preferentially incorporated into the outermost surface of the myelin sheath (Linington et al., 1988 ; Brunner multiple sclerosis. One of several candidate autoantigens is the myelin-oligodendrocyte glycoprotein (MOG) (Wekerle et al., 1989) , where a single immunoglobulin (Ig)-like domain (MOG Igd ) is exposed to the extracellular environment (Kroepfl streptomycin) and incubated at 37°C in 5% CO 2 (standard protocol). IL-2 (kindly donated by M. Gately and J. Sepinwall, et al., 1996) . This domain is unique in that it is the only protein structure known to induce both demyelinating Hoffmann/La Roche, Nutley, NJ, USA) was added to primary cultures and T-cell lines at final concentrations of 7.5 and autoantibody and encephalitogenic T-cell responses in EAE (Linington et al., 1993; Amor et al., 1994; 30 U/ml, respectively. Murine L cells were cultured in RPMI 1640 supplemented with 10% FCS (foetal bovine 1996) . Synergy between the immune effector mechanisms triggered by these responses results in a chronic/relapsing serum), 1% glutamine (0.2 M) and 1% penicillin/streptomycin. disease associated with extensive CNS demyelination in rats and primates (Linington and Lassmann, 1987; Adelmann et al., 1995; Johns et al., 1995; Genain et al., 1995; Genain Patients and healthy controls and Hauser, 1997; Weissert et al., 1998; Storch et al., 1998b) .
Peripheral blood was taken with informed consent every Moreover, demyelination in these models is characterized by 2-3 weeks from five healthy controls and five patients patterns of myelin vesiculation and immunoglobulin/neoC9 with relapsing-remitting (RR) multiple sclerosis for isolation deposition that reproduce those seen in a subset of multiple of MOG-reactive T-cell lines. All of these donors were typed sclerosis patients (Lucchinetti et al., 1996 (Lucchinetti et al., , 1998 for human leucocyte antigens (HLA) (Professor E. Albert, 1998; Storch et al., 1998a, b; Genain et al., 1999; Raine Laboratory for Immunogenetics, Ludwig Maximilians et al., 1999) .
University, Munich, Germany). Comparative analysis of the Elevated autoreactive MOG-specific T-cell (Sun et al., peripheral T-and B-cell responses to rhMOG Igd was 1991a; Kerlero de Rosbo et al., , 1997 Wallström et al., performed in 37 healthy controls and 37 multiple sclerosis 1998) and B-cell responses (Sun et al., 1991a; patients [10 primary chronic progressive (pCP), 10 secondary 1991) in multiple sclerosis have been described previously chronic progressive (sCP), 12 RR patients and five patients by several groups. However, as this is also the case for the with a first episode of neurological symptoms and laboratory autoimmune response to other myelin proteins in multiple and MRI features consistent with multiple sclerosis]. None sclerosis, the relevance of these observations with respect to of the patients had received either immunosuppressive or disease pathogenesis is uncertain. In the present study we immunomodulatory treatment during the last 6 months, or investigated the B-and T-cell responses to human MOG Igd corticosteroids during the last 6 weeks prior to blood in the blood of patients with multiple sclerosis and of healthy sampling. controls, using a highly purified recombinant human protein preparation (rhMOG Igd ) expressed in Escherichia coli.
We report the novel observation that although anti-MOG Igd
Antigens
autoantibodies are significantly more frequent in multiple Myelin basic protein (MBP) was purified from human sclerosis patients than in healthy controls, this is not brain according to standard protocols (Eylar et al., 1979) . accompanied by a corresponding proliferative T-cell response.
The purity of MBP was assessed by gel electrophoresis. However, analysis of MOG Igd -specific CD4 ϩ T-cell lines by Recombinant rat S100β was expressed and purified as intracytoplasmic staining for interferon (IFN)-γ and described elsewhere (Schmidt et al., 1997) . rhMOG Igd (amino interleukin (IL)-4 revealed the presence of both Th-1 and acids 1-125) was expressed in E. coli and purified by nickelTh-2 clones in the immune repertoire of both multiple chelate affinity chromatography on chelating Sepharose Fast sclerosis patients and healthy controls. Epitope mapping Flow (Pharmacia, Uppsala, Sweden) in 6 M urea (Brehm demonstrated that, although the specificity of this response et al., 1999) followed by preparative SDS (sodium dodecyl was heterogeneous, there was a clustering of epitopes in the sulphate) gel purification to remove endotoxin and other N-terminal region of the protein. The presence of MOG Igdbacterial contaminants. Homogeneity was assessed by SDSspecific Th-1 and Th-2 T cells together with MOG Igd -PAGE (polyacrylamide gel electrophoresis) followed by silver specific autoantibodies has obvious implications for the future staining. Protein concentration was determined using development of immunotherapies for multiple sclerosis.
Peterson's modification of the micro-Lowry method (SigmaAldrich, Deisenhofen, Germany). Antigens were stored at -20°C. The synthetic MOG peptides were purchased from Neosystem (Strasbourg, France) with the sequences shown
Material and methods
in Table 1 . The peptide purity was assessed by HPLC
Cell culture
(high-pressure liquid chromatography) analysis and mass Peripheral blood-derived mononuclear cells (PBMC) were spectrometry. isolated from EDTA (ethylene diamine tetraacetic acid)-buffered blood on a discontinuous density gradient (Lymphoprep, Nycomed, Oslo, Norway) (Boyum, 1974) . PBMC were cultured in RPMI 1640 supplemented with 5%
Isolation of MOG-reactive long term T-cell lines
PBMC (2 ϫ 10 5 /well) were cultured in 96-well round-bottom pooled human AB serum, 1% glutamine (0.2 M) and 1% penicillin/streptomycin (10 000 IU/ml penicillin/10 000 µg/ml microtitre plates (Nunc, Roskilde, Denmark) and challenged in the presence or absence of the above mAb (20-25 µg/ml (10 µg/ml each). Medium containing IL-2 (15 U/ml) was final concentration) in duplicate wells for 30 min. T-cell line added to the cultures every 4-5 days. After 4 weeks, cells (1 ϫ 10 5 /well) were added, and after an incubation rhMOG Igd -reactive cells were identified using a modification period of 30 min the MOG peptide recognized by the of the split-well technique (Meinl et al., 1993) . Briefly, particular line (10 µg/ml) was added to the wells. Labelling irradiated (50 Gy) autologous PBMC were used as antigenand harvesting were performed as described for proliferation presenting cells. Antigen-presenting cells (1 ϫ 10 5 /well) assays. To further define the restriction of the T-cell lines, Twere pre-incubated with rhMOG Igd (15 µg/ml), a recombinant cell line cells (1 ϫ 10 5 /well) were incubated with irradiated control protein (15 µg/ml) or without antigen as a negative (40-60 Gy) human HLA-DR-transfected mouse fibroblasts control. Each well of the primary culture was then split into (L cells; 2 ϫ 10 4 cells/well) in the presence of peptide three wells containing the preincubated antigen-presenting (10 µg/ml) for 68 h and proliferation was determined as cells. MOG reactivity was assessed microscopically for 3 described above. days. Specific proliferative aggregates were further expanded in the presence of IL-2 (final concentration 30 U/ml), then restimulated every 16-21 days with either rhMOG Igd or MOG peptides using irradiated autologous PBMC as antigen-
Characterization of T-cell lines by flow
presenting cells and fed with medium containing IL-2 cytometry (60 U/ml) every 3-4 days.
T-cell lines were phenotypically characterized by fluorescence-activated cell sorter (FACS) scanning (FACScan, Becton Dickinson, Heidelberg, Germany). Unlabelled mouse mAb (final concentration 1-2 µg/ml) to CD3, CD8 (DAKO,
Proliferation assays
Freshly isolated PBMC were cultured in 96-well microtitre Hamburg, Germany) and CD4 (Becton Dickinson) and a mouse IgG1 isotype control (Becton Dickinson) were visualplates (2 ϫ 10 5 /well) for 5 days. The following antigens were added at the beginning of the culture in triplicate:
ized with a FITC (fluorescein isothiocyanate)-labelled goat anti-mouse mAb (1-2 µg/ml; DAKO). The T-cell receptor rhMOG Igd (15 µg/ml), MOG peptides (10 µg/ml each), MBP (20 µg/ml), recombinant control antigen [recombinant rat (rr) Vβ region expressed was analysed using mAb (1-2 µg/ml) recognizing the following subfamilies: Vβ2, Vβ7, Vβ8, Vβ9, S100β, 15 µg/ml], tetanus toxoid (2 µg/ml; Behringwerke, Marburg, Germany), purified protein derivative from Vβ11, Vβ12, Vβ13.1, Vβ13.6, Vβ14, Vβ16, Vβ17, Vβ18, Vβ20, Vβ21.3, Vβ22, Vβ23 (Immunotech, Marseille, tuberculin (2 µg/ml; Statens Institute, Copenhagen, Denmark) and phytohaemagglutinin (2 µg/ml; Sigma, Deisenhofen, France), Vβ6.7, Vβ7.1 (Labgen, Frankfurt, Germany), Vβ3.1, Vβ5.1, Vβ5.2, Vβ5.3 and Vβ8.1 (T-Cell Diagnostics, Woburn, Germany). [ 3 H]Thymidine (0.2 µCi) was added during the last 18 h of culture. Cells were harvested and [ 3 H]thymidine Mass., USA). The intracellular cytokine profiles of the T-cell lines in incorporation was measured using a direct β-counter (Matrix TM 96 Direct Beta Counter, Packard, Frankfurt, Germany) response to stimulation were also characterized by FACS. MOG Igd -reactive T-cell line cells (1 ϫ 10 5 /well) were that yielded~20% of counts obtained by liquid scintillation counting. The criteria for a positive response were set at a stimulated according to standard protocols [PMA (phorbol-12-myristate-13-acetate) 5 µg/ml, ionomycin 250 ng/ml] for stimulation index Ͼ3 with an absolute value of Ͼ1000 c.p.m. Antigen specificity of the T-cell lines was determined using 3 h, the last 2 h in the presence of monensin (2 nmol/ml). T cells were then washed, fixed, permeabilized and labelled irradiated (50 Gy) autologous PBMC (1 ϫ 10 5 /well) preincubated in the presence or absence of antigen in 96-for IFN-γ (FITC, 1 µg/ml; Pharmingen, Hamburg, Germany) and IL-4 [PE (phycoerythrin), 1 µg/ml; Pharmingen] or the well microtitre plates. T-cell line cells (1 ϫ 10 5 /well) were 1st ϭ patients with a first manifestation of neurological symptoms consistent with multiple sclerosis; RR ϭ relapsing-remitting; sCP ϭ secondary chronic progressive; pCP ϭ primary chronic progressive.
appropriate isotype controls (negative control R-PE, 1 µg/ml, Western blot data were analysed with SPSS using nonparametric statistical (χ 2 ) tests. DAKO; negative control FITC, 1 µg/ml, Immunotech). (Table 2) . identifies both conformation-dependent and -independent
Results

Immunoblotting
The proportion of anti-MOG Igd antibody-positive samples was antibody responses to MOG Igd (Brehm et al., 1999) . After significantly higher in the multiple sclerosis patient group SDS-PAGE and blotting, nitrocellulose membranes were cut (54%) than in the random controls (excluding laboratory into 3-to 5-mm strips containing 1.5 µg MOG Igd per strip and workers exposed to MOG) (22%; P ϭ 0.023). Anti-MOG Igd then blocked with 5% low-fat milk powder in Tris-buffered antibodies were also detected in three of five laboratory workers saline containing 1% Tween 20 (milk-TBST). The strips were who regularly handled recombinant MOG preparations. then incubated with plasma diluted 1 : 500 in 2% milk-TBST Dividing the group of multiple sclerosis patients according to in mini-incubation trays (Bio-Rad, Munich, Germany) for 1 h clinical course revealed that the highest proportion of antiat room temperature. Preliminary studies established that this MOG Igd antibody-positive samples was found in the group plasma dilution provided the most discriminatory signal-towith a first clinical manifestation (5/5; P Ͻ 0.01 compared noise ratio for the detection of the anti-MOG Igd response. A with the random control group), followed by those with a RR goat anti-human IgG ϩ IgM [heavy and light (H and L) chains] course (8/12; P ϭ 0.01) and with an sCP course (5/10, P ϭ coupled to horseradish peroxidase (Dianova, Hamburg, 0.08). Among multiple sclerosis patients with a pCP disease Germany) was used as secondary antibody (100 ng/ml in 2% course, the number of anti-MOG Igd -antibody-seropositive milk-TBST) and incubated with washed strips for 45 min. The donors (2/10) was not significantly different from that seen in mouse monoclonal anti-MOG IgG1 antibody, purified from the random control population (Table 2 ; P ϭ 0.47). hybridoma 8-18C5 (Harlan Sera-Lab, Crawley Down, UK),
In contrast to the differences we observed in the anti-MOG Igd was used as a positive control (5-50 µg/ml in 2% milk-TBST).
antibody response, we did not detect any significant difference Goat anti-mouse IgG ϩ IgM (H and L) coupled to horseradish between the multiple sclerosis patients and healthy controls peroxidase (1 mg/ml; Dianova) was used at a dilution of with respect to the T-cell response in terms of the stimulation between 1 : 4000 and 1 : 10 000 in 2% milk-TBST. Antibody index obtained using either rhMOG Igd or synthetic MOG Igdbinding was detected by enhanced chemiluminescence using peptides. Furthermore, there was no difference between the Hyperfilm-ECL according to the manufacturer's instructions proliferative response to rhMOG Igd , the recombinant control (Amersham). Immunoreactivity of the coded plasma samples antigen (rrS100β) or MBP in individual assays (Fig. 1) . was assessed by three independent observers.
Peptide fine specificity of MOG-reactive T-cell Statistical analysis lines
ANOVA (analysis of variance) was performed using the SPSS In the absence of a proliferative response to either rhMOG Igd or the panel of MOG Igd -peptides in PBMC, we generated a statistics package for Windows for the stimulation indices. Fig. 2 Peptide specificity of the rhMOG Igd -reactive T-cell line HKcontrols, SI ϭ 13.6, SD ϭ 13.1; multiple sclerosis, SI ϭ 11.5, SD ϭ M3. The line shows a strong proliferative response to both 16.1), purified protein derivative from tuberculin (healthy controls, rhMOG Igd and MOG peptide 7 (amino acids 76-100) but no SI ϭ 10.9, SD ϭ 9.6; multiple sclerosis, SI ϭ 5.6, SD ϭ 7.6) and response to the recombinant control antigen or the other peptides. phytohaemagglutinin (healthy controls, SI ϭ 43.2, SD ϭ 43; multiple sclerosis, SI ϭ 65, SD ϭ 167).
peptide epitopes present in the N-terminal sequence of MOG (amino acids 1-60). Intriguingly, despite the broad range of MHC haplotypes provided by this panel of donors (Table 3) , panel of antigen-specific T-cell lines to further characterize the no T-cell lines were isolated that responded to the peptide rhMOG Igd -specific T-cell response. The age, sex, clinical status sequences 50-87 or 89-125. It was also noted that a response and HLA type of the donors are listed in Table 3 . Table 4 shows to peptide 3 (amino acids 27-50) was detected only in T-cell the peptide specificity of the total of 27 MOG-reactive T-cell lines derived from the control population ( Table 4 ). lines that were isolated from PBMC of five healthy controls and two patients with RR multiple sclerosis. The majority of the T-cell lines were isolated from cultures stimulated with rhMOG Igd (healthy controls: n ϭ 16/20; multiple sclerosis:
Cytokine production by MOG-reactive T-cell lines
In EAE induced in a non-human primate by sensitization with n ϭ 5/7; indicated in Table 4 by the letter M after the donor's initials), but other MOG-specific T-cell lines were isolated MOG, clinical disease can occur in association with a Th-2-like T-cell response, which may enhance the production of from cultures stimulated with the pool of synthetic peptides (indicated by the letter P after the donor's initials). T-cell lines MOG-specific autoantibodies (Genain et al., 1996) . We therefore investigated the synthesis of IFN-γ and IL-4 by the that did not exhibit a response to both the recombinant antigen and one or more peptides were discarded. Attempts to isolate MOG Igd -reactive T-cell lines for evidence of a similar cytokine pattern that may favour antibody production. MOG-reactive T-cell lines from three further RR multiple sclerosis patients, one of whom started immunomodulating
We were able to obtain sufficient cells for this study from 15 of the MOG Igd -reactive T-cell lines obtained from five of treatment with IFN-β during the investigation, were unsuccessful.
the donors. The T-cell lines were first expanded by several rounds of MOG Igd -specific restimulation followed by All the T-cell lines, irrespective of whether they were selected with protein or peptide, were specific for MOG and expansion in IL-2-containing medium. The T cells were then stimulated with PMA and ionomycin according to standard did not respond to control recombinant antigen (Fig. 2) , and all but four of the lines exhibited a stimulation index Ͼ10 when protocols to detect cytokine synthesis by intracellular FACS analysis. Only T-cell lines with Ͼ50% of T cells producing confronted with the appropriate peptide (Table 4) . Epitope mapping revealed that the majority of the T-cell lines (21/27) detectable amounts of IFN-γ and/or IL-4 after stimulation were taken into account. The T-cell lines were designated Th-1, Th-0 responded to only one of the nine overlapping peptides. The remainder exhibited multiple specificities, which in some cases or Th-2 according to the predominant T-helper type (Table 5 ).
The majority of the T-cell lines (60%) were of the Th-1 involved adjacent peptides, e.g. the response to peptides P3 and P4 (see Table 1 ) by the T-cell line CL-M1, suggesting that subset in that they synthesized only IFN-γ. A further four T-cell lines consisted of a dominant population of Th-0 T cells cothe response could be attributed to a single epitope within the overlapping amino acid sequence. In general there was no expressing both IFN-γ and IL-4, whilst one line (CL-M36) contained similar percentages of Th-0 and Th-2 T cells. Only difference in the peptide specificity of the T-cell lines derived from healthy controls and of those derived from multiple one T-cell line (ASt-M10C) expressed exclusively IL-4 and could therefore be assigned to the Th-2 T-cell subset. sclerosis patients. The majority of T-cell lines recognized The five donors with multiple sclerosis had established relapsing-remitting disease but were in clinical remission at the time propagation of the T-cell lines was attempted. P2  P3  P4  P5  P6  P7  P8  P9   HK-P1  60  9617  158  --------HK-P4  671  3514  112  --------HK-M3  111  10 950  ------1 1 0  --HK-M10  99  3603  ---70  -----HK-M20  52  1926  45  --------AS-M13  12  154  -155  -------AS-M15  31  1095  26  --------ASt-M2  360  2937  6  --------ASt-M4  435  3370  10  --------ASt-M1c  20  10 055  --609  ------ASt-M2c  19  2171  --459  ------ASt-M8c  129  8397  --71  ------ASt-M10c  970  10 616  --11  ------CL-P6  10  6648  625  ----5 4  ---CL-P7  20  6139  75  -354  277  -----CL-M1  142  5662  --53  50  -----CL-M27  33  4042  157  --------CL-M30  17  7587  --518  ------CL-M36  36  4330  -235  -------UB-M40  495  1169  ------2 . 9  --HW-M3  1208  4696  --3.8  ------HW-M6  262  5372  --5.8  ------HW-M8  44  6399  107  -122  25  -----HW-M9  172  6777  41  -10  ------TN-M6  141  2475  ---94  TN-U7  59  2160  ------4 9  --TN-P12  41  1567  --21  ---135  46  - T-cell lines designated 'M' were initially stimulated with MOG Igd and those designated 'P' with pooled synthetic MOG Igd -peptides. HK and AS were multiple sclerosis donors. ASt, CL, UB, HW and TN were healthy controls. In the present study we investigated the T-and B-cell responses to the extracellular Ig-like domain of human MOG (MOG Igd )
The percentages of positively stained cells in the categories Th-1 in the blood of patients with multiple sclerosis and in healthy helper T cells are represented in the immune repertoire of multiple sclerosis patients and normal subjects. Consistent with this observation, we found MOG Igd -reactive autoantibodies in Interestingly, six out of 12 T-cell lines from the three antia small proportion (22%) of random healthy controls. However, MOG Igd antibody-seropositive donors (HK, CL, ASt) produced anti-MOG autoantibodies were significantly more frequent significant amounts of IL-4 after stimulation (Th-0 or Th-2 (54%) in multiple sclerosis patients. subset responses), but no IL-4 production was seen in the three A pathogenic role for CNS antigen-specific T cells in lines obtained from the seronegative donors (HW, TN). multiple sclerosis is suggested by findings in EAE studies, in which the adoptive transfer of T cells specific for several different antigens induces an inflammatory response in the CNS (Wekerle et al., 1994; Berger et al., 1997) . The human
MHC restriction and T-cell receptor Vβ
T-cell response to autoantigens such as MBP, proteolipid
expression of MOG-reactive T-cell lines
protein and S100β, which have been defined as being FACScan identified all of the T-cell lines generated in this encephalitogenic in EAE, has been studied extensively (Martin investigation as members of the CD4 ϩ , α/β TCR T-cell subset et al., 1992; Hafler et al., 1996; Kondo et al., 1996; Greer et al., (data not presented) . Restriction analysis of 14 T-cell lines 1997; Schmidt et al., 1997; Stinissen et al., 1997; Trotter et al., using the anti-MHC antibody blocking assay demonstrated that 1997 , 1998 Tuohy et al., 1997) . In all cases, autoreactive T the proliferation of six T-cell lines was inhibited by ജ80% cells specific for these antigens are a component of the normal, and in four other lines by~50% by anti-HLA-DR mAb. No healthy immune repertoire, an observation that can now be inhibition was seen in the presence of mAb to HLA-DP, -DQ extended to include MOG. However, we were unable to confirm or MHC class I, which was used as a control (Fig. 3) . The recent reports that MOG induces a specific proliferative T-cell proliferation of four T-cell lines could not be inhibited by any response in primary PBMC cultures derived from multiple of the anti-MHC class II mAb that were available, but for two sclerosis patients but not from healthy controls (Kerlero de of these lines the response was shown to be restricted by Rosbo et al., , 1997 . DRB3*0202 (DR52) in the L-cell presentation assay.
Out of the entire panel of samples analysed, only one Analysis of surface TCR expression by these T-cell lines donor exhibited a stimulation index Ͼ3 in response to pooled using the available panel of TCR Vβ-specific mAb positively synthetic MOG peptides. The sensitivity of primary proliferaidentified the surface expression of TCR Vβ 8. 1, 13.1, 17, 20 tion assays is limited, however, and may be insufficient to and 22 by eight T-cell lines. However, the sample size is too detect the expansion of autoreactive T cells in PBMC cultures. small to make any comment as to the possibility of preferential Analysis of the frequency of T cells responding to myelin usage of any particular TCR Vβ chain in the context of the autoantigens by ELISpot suggests that this may indeed be the case, as this technique does detect increased T-cell responses MOG-specific T-cell response (Table 6 ). Minor peptide-specific responses are given in brackets (Table 4) . † ϭ Fine restriction could not be determined in L-cell presentation assays; -ϭ TCR Vβ expression could not be determined with the mAb used (see Material and methods); n.d. ϭ not done to MOG in multiple sclerosis patients. However, this reflects a 1998), since the number of T-cell lines from HLA-DR2-positive individuals analysed in our study was relatively small. generalized enhancement of the myelin-specific autoimmunity rather than a selective response to MOG (Sun et al., 1991a, b;  Unfortunately, not all of the MOG/peptide-reactive T-cell lines could be fully characterized with respect to TCR Vβ expression Fredrikson et al., 1992; Olsson et al., 1992; Wallström et al., 1998) . It should also be noted that in this study we analysed and MHC restriction, either because the necessary anti-TCR Vβ mAb and human MHC class II-transfected L cells were only the response to the Ig domain of MOG and cannot exclude the possibility that immunodominant T-cell epitopes of MOG unavailable, or because the number of these short-term T-cell lines was insufficient for all assays. Nevertheless, the T-cell are located within the transmembrane or cytoplasmic domains of the protein. It is also important to consider that the 'activation lines were clearly heterogeneous with respect to all the parameters tested, and in this regard they resemble MBPstatus' of the T cells at the time of isolation is unknown. Obviously, T cells anergic to MOG would not be detected in specific T-cell lines (Meinl et al., 1993) . In contrast to the absence of any factor that distinguished the current proliferation assay. Moreover, preactivated MOGreactive T cells might undergo apoptosis when challenged with the MOG Igd -specific T-cell repertoire in multiple sclerosis from that seen in normal controls, we noted that the frequency of antigen in vitro. These mechanisms may explain why we were unable to isolate MOG-reactive T-cell lines from three of the anti-MOG Igd antibody-seropositive donors was far higher in multiple sclerosis patients than in normal controls (Table 2) . multiple sclerosis patients (BM, MH and SS), one of whom (SS) was undergoing IFN-β treatment.
The high frequency of anti-MOG antibody responses in multiple sclerosis patients is consistent with a retrospective Although no significant primary T-cell response to MOG Igd could be demonstrated, it was possible to select MOG Igdstudy that analysed a large panel of paired serum and CSF samples from multiple sclerosis patients and disease controls reactive T-cell lines from the PBMC of both multiple sclerosis patients and healthy controls, giving us some insight into the (Reindl et al., 1999) . In the present study, fewer patients classified as having a primary progressive course of disease nature of the MOG-specific T-cell repertoire. All the T-cell lines selected using recombinant MOG Igd in vitro recognized were seropositive for anti-MOG antibodies compared with patients having either first lapse/RR or an sCP course. This one or more of a panel of nine overlapping synthetic MOG Igd peptides, with a bias towards epitopes located within amino might support the hypothesis of a different pathogenetic background between these groups of patients (Thompson et al., acid sequences 1-26 and 27-50, which together account for 60% of the identified peptide specificities. Peptide 63-87, 1997) . Longitudinal studies are currently in progress to determine whether this actually reflects a loss of the antirecently reported to be immunodominant in HLA-DR2-positive multiple sclerosis patients assessed by ELISpot MOG response during the course of multiple sclerosis, or differentiates pathologically distinct subsets of progressive (enzyme-linked immunoabsorbent spot assay) analysis of PBMC (Wallström et al., 1998) , did not stimulate any of the disease.
In the present study, the sample numbers are too small to MOG Igd -reactive T-cell lines (Table 4 ). This does not necessarily contradict the previous study (Wallström et al., determine whether or not the T-cell repertoire of anti-MOG Igd antibody-positive donors is associated with any specific rational therapeutic choices to be made with respect to treatments that target the humoral arm of the immune response, cytokine profile. However, the three T-cell lines available from anti-MOG Igd antibody-negative donors (TN and HW) such as plasmapheresis and intravenous Ig (Fazekas et al., 1997) . Conversely, this would also provide a rational basis for produced IFN-γ and no IL-4, whereas six T-cell lines obtained from three antibody-positive donors (multiple sclerosis patient the avoidance of therapeutic strategies that may favour B-cell activation (Hohlfeld, 1997) . The harmful consequences of this HK and healthy controls CL and ASt) synthesized IL-4, either exclusively or together with IFN-γ. This observation is were clearly seen in the marmoset model of MOG-induced EAE, in which high-dose soluble antigen treatment induced a preliminary, but suggests a functional correlation between the presence or absence of anti-MOG Igd antibody and antigenhigh-titre antibody response that ultimately proved lethal to the treated animals (Genain et al., 1996) . specific IL-4 synthesis. However, it will be necessary to generate a far larger set of MOG Igd -reactive T-cell lines from both anti-MOG Igd antibody-positive and -negative donors to confirm this hypothesis.
